Myelomas
214828 A Phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (TI-NDMM)-DREAMM-10
- Details
ClinicalTrials.gov ID:
NCT06679101
Diagnosis Type:
NA
USOR Number:
- Address
,
P: